Vitamin E

Vitamin E has been studied in 386 papers since 1980: 35 trials and 145 observational studies in people, 52 in animals, 7 in cells, 143 reviews; 96 in the past year. The newest paper, Nov 19, 2026: “Protective effects of intermittent fasting and vitamin E against hyperthyroidism-associated ocular complications in Wistar rats”.

Intervention

386 papers study it189 more mention it202 findingsUpdated

PubChemMeSH

Research on it is growing about as fast as aging research as a whole: 18 papers in the latest year counted

More supplements

15 new papers in 30 daysSee all 573 papers on vitamin E

At a glance

Independent labs found the same change in worms or flies, mice and people. 106 independent labs in 25 countries; 119 trials, 4 about aging, 68 with no results posted.

“yielded hazard ratios of 0.88 (95% CI, 0.64-1.20) for vitamin E, 0.83 (0.60-1.13) for selenium, and 1.00 (0.75-1.35) for the combination compared with placebo”
Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE)JAMA neurology2017doi:10.1001/jamaneurol.2016.5778

28 of its findings point the other way.

Worms or flies, mice and humans: replicated by independent labs. Cells: a single group.
  • 106 independent labs in 25 countries
  • 28 findings against
  • 119 trials, 4 about aging, 68 with no results posted
  • Funders: National Institutes of Health and others
  • 11 of 208 findings with company ties
  • Human trial35
  • Humans145
  • Animals47
  • Model organisms5
  • Cells7
  • In silico3

11 studies gave vitamin E to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on japanese knee osteoarthritis measure score

no change: Has no effect on physical function

down: Decreases inflammatory markers

Randomized trial24 weeks80 peopleWomen71.9 ± 5.6 yearsOlder adults; Postmenopausal women; Postmenopausal women with symptomatic knee osteoarthritisMedicine, Oct 16, 2026

down: Decreases LDL-C

Randomized trial90 peopleGeneral population; in healthy volunteersNutrition, metabolism, and cardiovascular diseases : NMCD, Feb 25, 2025

down: Decreases hot flashesnearly one-third of the base amount, P = 0.002

down: Decreases triglycerideP < 0.001

down: Decreases aspartate aminotransferaseP = 0.007

Randomized trialeight weeks84 peopleWomenPostmenopausal womenHealth care for women international, Sep 2, 2022

down: Decreases CTX-0.003 ± 0.09 versus 0.121 ± 0.15 with placebo

Randomized trial12 weeks52 peopleWomenPostmenopausal women; Postmenopausal osteopenic womenNutrients, Nov 25, 2021

down: Decreases hot flashesadjusted mean difference -8.7, 95% CI -0.6 to -15.0, P = 0.029

no change: Has no effect on anxietyP > 0.05

Randomized trial8 weeks93 peopleWomen51.7 yearsPostmenopausal women; postmenopausal hot flashesComplementary therapies in medicine, Nov 26, 2019

What did lifespan studies of vitamin E find?

DrugAge

DrugAge records 30 results from 12 papers: 10 in Z. paravittiger, 9 in C. elegans, 4 in P. tetraurelia and 4 other species. Average lifespan is the mean or the median, as each paper reports it.

What did studies of vitamin E find?

89

Studies of vitamin E measured 89 outcomes; the most studied are lifespan (12 studies), oxidative stress and ROS signaling (8) and cognitive function (5).

Lifespan

upin mice5no changein mice4upin worms3no changein T. commodus1+17%

12 studies
  1. Vitamin E extends lifespan in worms (gpx-quad mutant background).

    Model organismsgpx-quad mutant background

  2. Vitamin E extends lifespan in worms (gas-1(fc21) mitochondrial complex I disease model).

    Model organismsgas-1(fc21) mitochondrial complex I disease model

  3. Vitamin E showed no clear effect on lifespan in T. commodus.

    Model organismsDL-alpha-tocopherol

  4. Vitamin E extends lifespan in MRL/lpr mice.

    Animalsin MRL/lpr mice250 mg/kg vs 500 mg/kgfemales

  5. Vitamin E extends lifespan in mice (+17%).

    Animals5.0 g alpha-tocopherol acetate/kg of foodmales

  6. Vitamin E extends lifespan in mice (+40% (61 +/- 4 wk to 85 +/- 4 wk)).

    Animals5.0 g alpha-tocopherol acetate/kg of foodmales

  7. Vitamin E extends lifespan in female NZB/W F1 mice fed oxidised frying oil.

    Animalsin female NZB/W F1 mice fed oxidised frying oilall-rac-alpha-tocopheryl acetate550 mg/kg dietfemales

  8. Vitamin E extends lifespan in worms (wild-type).

    Model organismswild-type

  9. Vitamin E extends lifespan in mice (+25-20% (median and maximal)).

    Reviewmales

  10. Vitamin E showed no clear effect on lifespan in mice (median lifespans: 804, 830 and 801 days).

    Animalsdietthroughout life, from the time of conception until death

All 14

Oxidative stress and ROS signaling

downin mice4downin E. caballus1no changein mice1downin rats1+1

8 studies
  1. Vitamin E decreases oxidative stress and ROS signaling in rats (lithium-treated aged rats).

    Animalslithium-treated aged ratsliver100 mg/kg every other dayfour weeksn = 48

  2. Vitamin E decreases oxidative stress and ROS signaling in mice (higher doses showed greater effects).

    Animalshigher doses showed greater effects100, 200, or 400 mg/kg28 daysmales

  3. Vitamin E decreases oxidative stress and ROS signaling in mice.

    Animalsheart and brain100, 200, and 400 mg/kg28 days

  4. Vitamin E decreases oxidative stress and ROS signaling.

    Review

  5. Vitamin E decreases oxidative stress and ROS signaling in mice.

    Animalsantioxidant supplementationbrown adipose tissue

  6. Vitamin E decreases oxidative stress and ROS signaling in E. caballus (exercise-induced oxidative stress).

    Reviewexercise-induced oxidative stress

  7. Vitamin E decreases oxidative stress and ROS signaling in mice.

    Reviewbrain

  8. Vitamin E showed no clear effect on oxidative stress and ROS signaling in mice.

    Animalsheart1.65 g/kg13 weeks

More on Oxidative stress and ROS signaling

Cognitive function

no changein humans4mediatesin humans1

5 studies
  1. Vitamin E showed no clear effect on cognitive function in humans.

    Human trial3 months

  2. Vitamin E showed no clear effect on cognitive function in humans (Down syndrome).

    Human trialDown syndromeoral1,000 IU twice daily3 yearsn = 337

  3. Vitamin E was not clearly linked with cognitive function in humans (r = 0.027, p = 0.806).

    Humansn = 85

  4. Vitamin E is linked with cognitive function in humans (dietary fiber-cognitive function association) (85.0% mediation).

    Humansdietary fiber-cognitive function associationn = 2,713

  5. Vitamin E showed no clear effect on cognitive function in humans (Non-demented adults).

    ReviewNon-demented adults≥3 months

Mortality

no changein humans2upin rats1downin reviews1

4 studies
  1. Vitamin E showed no clear effect on mortality in humans (Down syndrome) (p = 0.086).

    Human trialDown syndromeoral1,000 IU twice daily3 yearsn = 337

  2. Vitamin E was not clearly linked with mortality in current smokers.

    Humansin current smokersmedian follow-up of 119.7 months

  3. Vitamin E decreases mortality.

    Review

  4. Vitamin E increases mortality in rats (streptozocin-induced diabetes) (84% died by 6 mo).

    Animalsstreptozocin-induced diabetes100 IU vitamin E/kg chow6 momales

Triglyceride

downin humans2

2 studies
  1. Vitamin E decreases triglyceride in humans (P < 0.001).

    Human trialcapsules200 IU twice/dailyeight weeksfemales

  2. Vitamin E is linked with lower triglyceride in Brazilian (ISA) and U.S. Hispanic/Latino (NHANES) participants.

    Humansin Brazilian (ISA) and U.S. Hispanic/Latino (NHANES) participants

More on Triglyceride

Inflammation

downin humans1downin reviews1

2 studies
  1. Vitamin E is linked with lower inflammation in humans (P < .05).

    Humans

  2. Vitamin E decreases inflammation.

    Review

More on Inflammation

Liver fibrosis

downin humans1downin rats1

2 studies
  1. Vitamin E decreases liver fibrosis in rats (lithium toxicity).

    Animalslithium toxicityliver100 mg/kg every other dayfour weeksn = 48

  2. Vitamin E decreases liver fibrosis in humans (obesity-linked liver disease).

    Reviewobesity-linked liver disease

LDL-C

downin humans1upin rats1

2 studies
  1. Vitamin E decreases LDL-C in healthy volunteers.

    Human trialin healthy volunteersn = 90

  2. Vitamin E increases LDL-C in the CV group.

    Animalsin the CV groupliver

More on LDL-C

SIRT1

upin mice2

2 studies
  1. Vitamin E increases SIRT1 in mice (particularly at higher doses).

    Animalsparticularly at higher doses100, 200, or 400 mg/kg28 daysmales

  2. Vitamin E increases SIRT1 in mice (gene expression measured in heart and hippocampus).

    Animalsgene expression measured in heart and hippocampusheart and hippocampus100, 200, and 400 mg/kg28 days

More on SIRT1

Hot flashes

downin humans2

2 studies
  1. Vitamin E decreases hot flashes in humans (nearly one-third of the base amount, P = 0.002).

    Human trialcapsules200 IU twice/dailyeight weeksfemales

  2. Vitamin E decreases hot flashes in humans (postmenopausal hot flashes) (adjusted mean difference -8.7, 95% CI -0.6 to -15.0, P = 0.029).

    Human trialpostmenopausal hot flashestablets200 IU/day8 weeksfemalesn = 93

Dementia

no changein humans2HR 0.88

2 studies
  1. Vitamin E showed no clear effect on dementia in humans (compared with placebo; Cox model adjusted for demographics and baseline comorbidities) (HR 0.88 (95% CI 0.64-1.20)).

    Human trialcompared with placebo; Cox model adjusted for demographics and baseline comorbiditiesmalesn = 7,338

  2. Vitamin E showed no clear effect on dementia in humans (Down syndrome) (11%/year).

    Human trialDown syndromeoral1,000 IU twice daily3 yearsn = 337

More on Dementia

NAFLD Activity Score

downin humans1

1 study
  1. Vitamin E decreases NAFLD Activity Score in humans (change in mean score, −1.8 vs −0.7).

    Human trial96 weeks

  2. Vitamin E decreases NAFLD Activity Score in humans (pediatric NAFLD) (-1.8 vs -0.7, P = .02).

    Human trialpediatric NAFLD800 IU daily96 weeksn = 58

More on NAFLD Activity Score

Metabolic dysfunction-associated steatohepatitis

downin humans1

1 study
  1. Vitamin E decreases metabolic dysfunction-associated steatohepatitis in humans (58% vs 28%).

    Human trial96 weeksn = 121

  2. Vitamin E decreases metabolic dysfunction-associated steatohepatitis in humans (pediatric NASH) (58% vs 28%, P = .006).

    Human trialpediatric NASH800 IU daily96 weeksn = 43

More on Metabolic dysfunction-associated steatohepatitis

Alanine aminotransferase

no changein humans1

1 study
  1. Vitamin E showed no clear effect on alanine aminotransferase in humans (26% vs 17%).

    Human trial96 weeks

  2. Vitamin E showed no clear effect on alanine aminotransferase in humans (pediatric NAFLD) (26% vs 17%, P = .26).

    Human trialpediatric NAFLD800 IU daily96 weeksn = 58

More on Alanine aminotransferase

Inflammatory markers

downin humans1

1 study
  1. Vitamin E decreases inflammatory markers in humans.

    Human trialWithin-group change during vitamin E plus home exercise; no significant between-group difference24 weeksfemales

More on Inflammatory markers

All 89

What is vitamin E linked with?

58

Studies link vitamin E with 58 measures, most often cognitive impairment (4 studies), mortality (3) and telomere length (3).

Cognitive impairment

downin humans4OR 0.94

4 studies
  1. Vitamin E is associated with cognitive impairment in humans.

    Humans

  2. Vitamin E is linked with a lower risk of cognitive impairment in humans (OR = 0.94, 95% CI 0.91-0.97).

    Humansn = 2,255

  3. Vitamin E is linked with a lower risk of cognitive impairment in humans.

    Humans

  4. Vitamin E is associated with cognitive impairment in humans.

    Reviewdietary component or multivitamin supplement

More on Cognitive impairment

Mortality

downin humans3HR 0.68

3 studies
  1. Vitamin E is linked with a lower risk of mortality in former smokers and non-smokers.

    Humansin former smokers and non-smokersmedian follow-up of 119.7 months

  2. Vitamin E is associated with mortality in humans (US NHANES cohort; multivariable-adjusted association) (32% lower mortality risk; HR 0.68, 95% CI 0.55-0.84).

    HumansUS NHANES cohort; multivariable-adjusted associationhighest versus lowest tertilen = 12,977

  3. Vitamin E is linked with a lower risk of mortality in humans (fully adjusted model) (Q4: 0.77 [0.63, 0.94]).

    Humansfully adjusted model

Telomere length

mixedin humans1downin humans1upin humans1

3 studies
  1. Vitamin E is associated with telomere length in humans.

    Humansn = 10,793

  2. Vitamin E is associated with telomere length in humans (established cardiovascular disease; inadequate versus adequate vitamin E intake) (Shorter LTL with inadequate intake; p = .004, .015, and .005 across three dietary recommendations).

    Humansestablished cardiovascular disease; inadequate versus adequate vitamin E intakeleukocyten = 1,002

  3. Vitamin E is associated with telomere length in humans.

    Humansfrom foodsleukocyte DNAfemalesn = 586

More on Telomere length

Sarcopenia

downin humans3OR 0.14

3 studies
  1. Vitamin E is linked with a lower risk of sarcopenia in humans (NHANES 2011-2018).

    HumansNHANES 2011-2018n = 9,436

  2. Vitamin E is associated with sarcopenia in humans (subcomponent analysis of CDAI).

    Humanssubcomponent analysis of CDAI

  3. Vitamin E is linked with a lower risk of sarcopenia in humans (highest vs lowest quantile) (OR 0.14, CI 0.04-0.49).

    Humanshighest vs lowest quantilen = 1,345

More on Sarcopenia

Chronic kidney disease

downin humans2OR 0.5–0.869

2 studies
  1. Vitamin E is associated with chronic kidney disease in humans (Simultaneous adjustment for total energy, protein, sodium, potassium, and phosphorus) (OR 0.869, 95% CI 0.768–0.982).

    HumansSimultaneous adjustment for total energy, protein, sodium, potassium, and phosphorusn = 8,676

  2. Vitamin E is associated with chronic kidney disease in humans (OR 0.50, 95% CI: 0.43–0.80).

    Humans

More on Chronic kidney disease

Cognitive function

downin humans2OR 0.73

2 studies
  1. Vitamin E is associated with cognitive function in multivariate models.

    Humansin multivariate modelsn = 5,591

  2. Vitamin E is linked with a lower risk of cognitive function in humans (elevated dietary intake) (OR = 0.73, 95% CI: 0.56-0.94).

    Humanselevated dietary intake

Age-related macular degeneration

downin humans2

2 studies
  1. Vitamin E is associated with age-related macular degeneration in humans.

    Humans

  2. Vitamin E lowers the risk of age-related macular degeneration in humans.

    Review

More on Age-related macular degeneration

Metabolic syndrome

downin humans1mixedin humans1

2 studies
  1. Vitamin E is linked with a lower risk of metabolic syndrome in U.S. Hispanic/Latino participants (NHANES).

    Humansin U.S. Hispanic/Latino participants (NHANES)

  2. Vitamin E is associated with metabolic syndrome in humans (P < .01).

    Humans

More on Metabolic syndrome

Prostate cancer

upin humans1downin humans1

2 studies
  1. Vitamin E raises the risk of prostate cancer in men.

    Reviewin men

  2. Vitamin E lowers the risk of prostate cancer in high-risk groups like smokers.

    Reviewin high-risk groups like smokers

More on Prostate cancer

Osteoporosis

downin humans2OR 0.652–0.96

2 studies
  1. Vitamin E is linked with a lower risk of osteoporosis in humans (OR 0.96, 95% CI 0.93-0.98).

    Humansn = 5,800

  2. Vitamin E is linked with a lower risk of osteoporosis in humans (Q4 vs first quartile) (OR 0.652; 95% CI 0.463-0.918).

    HumansQ4 vs first quartilen = 5,618

More on Osteoporosis

All 58

Has vitamin E been tested in people?

4 of 119 about aging

Yes: 35 trials and 145 observational studies in people have been published, and 119 trials are registered.

Every condition in trials

40 of 147

Stopped

  • NCT00809458TerminatedProstatic neoplasm

    Low rate of accrual.

  • NCT00515736TerminatedCritical illness

    enrollment was completed

  • NCT00740714TerminatedParkinson's disease

    The investigational drug is unlikely to demonstrate efficacy over placebo for this indication. However, no safety issues were discovered.

  • NCT00152841TerminatedCrohn's disease

    Lack of patients

  • NCT01897792TerminatedHealthcare-associated pneumonia

    Inability to recruit patients that meet inclusion criteria.

  • NCT02758990TerminatedAnxiety

    Recruiting and financial constraints

All 7

Who is developing vitamin E?

1 company: BREGO Life Sciences.

Companies
  • BREGO Life Sciencesdiabetic foot ulcer, diabetic symmetrical polyneuropathy

Trial sponsors

Funding

3 grants since 2018

National Institute of Neurological Disorders and Stroke$1.4MJapan Society for the Promotion of Science¥4.3MNational Institute of Allergy and Infectious Diseases$20.1K

Latest

Dec 2025: 13Jan 2026: 15Feb 2026: 16Mar 2026: 12Apr 2026: 8May 2026: 11Jun 2026: 1Jul 2026: 9Aug 2026: 8Sep 2026: 7Oct 2026: 14Nov 2026: 5119 papers in 12 months

See all 573 papers on vitamin E